Dr. Cheryl Jorcyk is director of clinical translational research. She is a professor in both the Department of Biological Sciences and in the Biomolecular Research Ph.D. Program.
Currently, her lab focuses on studying the role of the inflammatory factor Oncostatin M (OSM) in breast cancer invasion and metastasis, and translational studies to develop a novel therapeutic to block OSM are underway. She first began studying OSM and its function in tumor progression through collaboration with the Boise VA Medical Center.
Jorcyk is chair of the Boise State University Biomedical Institutional Review Board for the Protection of Human Subjects committee and a member of the Regional Advisory Workgroup for University of Washington ITHS. She has received clinical/translational research training at the Dana-Farber Cancer Institute in Boston through the American Association for Cancer Research.
She earned her Ph.D. in biology from Johns Hopkins University and her undergraduate degree, also in biology, from Pennsylvania State University. She did her postdoctoral fellowship at the National Cancer Institute, National Institutes of Health.